PHAXIAM Therapeutics S.A. (0QSS.L)

EUR 1.76

(1.03%)

Total Assets Summary of PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.'s latest annual total assets in 2023 was 51.3 Million EUR , up 12.0% from previous year.
PHAXIAM Therapeutics S.A.'s latest quarterly total assets in 2024 Q2 was 39.11 Million EUR , down 0.0% from previous quarter.
PHAXIAM Therapeutics S.A. reported annual total assets of 45.81 Million EUR in 2022, down -31.39% from previous year.
PHAXIAM Therapeutics S.A. reported annual total assets of 66.76 Million EUR in 2021, down -16.96% from previous year.
PHAXIAM Therapeutics S.A. reported quarterly total assets of 39.11 Million EUR for 2024 Q2, down 0.0% from previous quarter.
PHAXIAM Therapeutics S.A. reported quarterly total assets of 65.53 Million EUR for 2023 Q1, up 43.05% from previous quarter.

Annual Total Assets Chart of PHAXIAM Therapeutics S.A. (2023 - 2012)

Historical Annual Total Assets of PHAXIAM Therapeutics S.A. (2023 - 2012)

Year	Total Assets	Total Assets Growth
2023	51.3 Million EUR	12.0%
2022	45.81 Million EUR	-31.39%
2021	66.76 Million EUR	-16.96%
2020	80.4 Million EUR	-32.18%
2019	118.54 Million EUR	-29.37%
2018	167.84 Million EUR	-14.04%
2017	195.26 Million EUR	334.23%
2016	44.96 Million EUR	-15.16%
2015	53 Million EUR	30.53%
2014	40.6 Million EUR	126.24%
2013	17.94 Million EUR	76.94%
2012	10.14 Million EUR	0.0%

Year	Total Assets	Total Assets Growth
2024 Q1	- EUR	-100.0%
2024 Q2	39.11 Million EUR	0.0%
2023 Q1	65.53 Million EUR	43.05%
2023 FY	51.3 Million EUR	12.0%
2023 Q3	- EUR	-100.0%
2023 Q4	51.3 Million EUR	0.0%
2023 Q2	65.53 Million EUR	0.0%
2022 Q2	65.98 Million EUR	0.0%
2022 Q1	- EUR	-100.0%
2022 Q3	- EUR	-100.0%
2022 Q4	45.81 Million EUR	0.0%
2021 Q1	- EUR	-100.0%
2021 Q2	83.8 Million EUR	0.0%
2021 Q4	66.76 Million EUR	0.0%
2020 Q2	89.1 Million EUR	0.0%
2020 Q1	- EUR	-100.0%
2020 Q4	80.4 Million EUR	0.0%
2019 Q3	136.7 Million EUR	-6.08%
2019 Q4	118.54 Million EUR	-13.28%
2019 Q2	145.55 Million EUR	0.0%
2019 Q1	- EUR	-100.0%
2018 Q4	167.84 Million EUR	0.0%
2018 Q2	182.15 Million EUR	0.0%
2018 Q1	- EUR	-100.0%
2017 Q4	195.26 Million EUR	0.0%
2017 Q1	- EUR	-100.0%
2017 Q2	99.3 Million EUR	0.0%
2016 Q2	44.37 Million EUR	0.0%
2016 Q1	- EUR	-100.0%
2016 Q4	44.96 Million EUR	0.0%
2016 Q3	44.96 Million EUR	1.33%
2015 Q2	36.1 Million EUR	0.0%
2015 Q1	36.1 Million EUR	-11.1%
2015 Q3	53 Million EUR	46.82%
2015 Q4	53 Million EUR	0.0%
2014 Q4	40.6 Million EUR	0.0%
2014 Q2	14.9 Million EUR	0.0%
2014 Q1	14.9 Million EUR	-16.95%
2014 Q3	40.6 Million EUR	172.4%
2013 Q3	17.94 Million EUR	0.0%
2013 Q1	- EUR	-100.0%
2013 Q4	17.94 Million EUR	0.0%
2012 Q4	10.14 Million EUR	0.0%

Peer Total Assets Comparison of PHAXIAM Therapeutics S.A.

Name	Total Assets	Total Assets Difference
Boiron SA	590.2 Million EUR	91.307%
Laboratorios Farmaceuticos Rovi, S.A.	799.88 Million EUR	93.586%
Vetoquinol SA	692.23 Million EUR	92.588%
Valneva SE	469.39 Million EUR	89.069%
AB Science S.A.	25.49 Million EUR	-101.212%
Nanobiotix S.A.	93.89 Million EUR	45.358%
Vivoryon Therapeutics N.V.	30.82 Million EUR	-66.424%
BioSenic S.A.	9.55 Million EUR	-436.74%
ABIVAX Société Anonyme	327.06 Million EUR	84.313%
Formycon AG	890.36 Million EUR	94.238%